Please assess the completion status of the following clinical trial:

Trial Title: Effects of Rosuvastatin on Carotid Artery Plaques in Patients With Inflammatory Joint Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Women and men with RA, AS and other inflammatory forms of arthritis, aged 35-80 years.~2. Cholesterol plaques demonstrated in carotid artery by ultrasound.~3. Informed consent.~Exclusion Criteria:~1. Concomitant statin treatment~2. Arterial fibrillation or others with chronic irregular heart rhythm (because of CT).~3. Contraindication to statin treatment.~   * Hypersensitivity to statins~  * Liver disease with ASAT/ALAT ≥ twice the upper normal limit~  * Previous statin-induced myopathy or severe hypersensitivity reactions to other statins~  * Raised creatinine (because of contrast medium)~  * Pregnancy or breast feeding~  * Fertile women who do not use contraceptives~  * Cyclosporine treatment~  * Treatment with medicinal products that have a known interaction with Rosuvastatin~  * Uncontrolled hypothyroidism defined as TSH \> 1.5 times ULN at the first visit (because of the connection between myopathy and hypothyroidism with statin treatment)~  * Creatinine clearance \< 30 ml/min and \<60 ml/min with a Rosuvastatin dose of 40 mg per day~4. Secondary hyperlipidemia~   * Primary hyperthyroidism~  * Nephrotic syndrome, creatinine \> 2 mg/dl~  * Uncontrolled diabetes mellitus (HbA1C \> 10 %)~  * Plasma Triglycerides \> 6.8 mmol/l~5. Other diseases or treatment that reduces the safety, or treatment with Rosuvastatin which would interfere with the end points of the study~   * Heart failure: NYHA class III B/IV~  * Haemodynamically significant valve defects~  * Established statin treatment~  * Gastrointestinal disease/treatment that can give malabsorption of Rosuvastatin~  * Cancer~  * Severe psychiatric disease~  * Life-threatening ventricular arrhythmias~  * Other medication that increases the risk of rhabdomyolysis~  * Known abuse of alcohol~  * Participation in other studies

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Rosuvastatin intervention (Type: EXPERIMENTAL): Patients \> 70 years will be given Rosuvastatin of 5 mg a day, uptitering the dose until the LDL level of 1.6-1.8 mmol/l has been reached. Patient \<70 years, strat on Rosuvastatin 20 mg a day, uptitered to 40 mg a day, with the LDL of 1.6-1.8 mmol/l. -1.8 mmol/l. The objective is that all the participants should have reached a LDL level of 1.6-1.8 mmol/l 3 months after the start of the study. The participants will remain on Rosuvastatin medication for a total of 18 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).